FDA/Duke Partnership Will Work On Cardiac Markers, Form Consortium
Executive Summary
FDA's partnership with the Duke Clinical Research Institute to develop tools for identifying the potential cardiac effects of drugs and devices will examine gender differences as one of its first projects
You may also be interested in...
ECG Warehouse May Be Model For Critical Path FDA/Industry Partnerships
FDA's "ECG warehouse" could be a prototype for cardiovascular safety collaborations between FDA and industry under the Critical Path initiative, Center for Drug Evaluation & Research Deputy Director Douglas Throckmorton said Oct. 11
QT Guidance Reducing Number Of Drugs Leaving Early Development, Firms Say
Stricter guidelines on QT prolongation are forcing manufacturers to drop compounds earlier in the development process, participants said during an FDA/Duke Cardiac Safety and Critical Path Initiative Think Tank meeting Oct. 11
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue